Payment overview · 2025
General Payments
$2,416.10
132 reported records · 32 companies
Healthcare provider profile · identity verified
Ryan C Su, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SAVANNAH, GA · NPI 1487383675
Verified facts
What the public records show
CMS Open Payments records show Ryan C Su, FNP-C received $2,416.10 in general payments during 2025 across 132 reported records.
ABBVIE INC. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $417.70 | 17.3% | 23 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $253.94 | 10.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $219.02 | 9.1% | 16 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $161.92 | 6.7% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $128.28 | 5.3% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.95 | 4.5% | 8 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $90.06 | 3.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.39 | 3.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.79 | 3.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.19 | 3.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.11 | 3.0% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $67.20 | 2.8% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $63.46 | 2.6% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $58.10 | 2.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.34 | 2.2% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $50.63 | 2.1% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $46.04 | 1.9% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $45.11 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $35.02 | 1.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.73 | 1.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.09 | 1.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.27 | 1.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.27 | 1.1% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $21.95 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.72 | 0.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.94 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.79 | 0.8% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.97 | 0.7% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $17.52 | 0.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.45 | 0.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.71 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.44 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,416.10 | 132 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $286.31 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $233.80 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $203.77 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $134.59 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $132.10 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $132.10 | 10 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $108.95 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $90.71 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $89.39 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $83.90 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $83.79 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.69 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.11 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $67.20 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $66.64 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $66.64 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $63.46 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $59.82 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $58.10 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $50.63 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.85 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $45.11 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $45.11 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $45.11 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $45.11 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $35.02 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.31 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.34 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $30.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.27 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| LO LOESTRIN FE Normalized: lo loestrin fe |
Drug | ABBVIE INC. | $26.55 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 132 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
132 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 167 | 53 |
| Mounjaro | Tirzepatide | 132 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 127 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 117 | 58 |
| Ozempic | Semaglutide | 111 | 32 |
| Tramadol Hcl | Tramadol Hcl | 108 | 41 |
| Methylprednisolone | Methylprednisolone | 99 | 94 |
| Azithromycin | Azithromycin | 92 | 83 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 69 | 40 |
| Gabapentin | Gabapentin | 68 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 52 |
| Lisinopril | Lisinopril | 57 | 33 |
| Omeprazole | Omeprazole | 57 | 32 |
| Furosemide | Furosemide | 55 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 42 |
| Losartan Potassium | Losartan Potassium | 48 | 26 |
| Famotidine | Famotidine | 47 | 25 |
| Metformin Hcl | Metformin Hcl | 45 | 25 |
| Trazodone Hcl | Trazodone Hcl | 45 | 23 |
| Potassium Chloride | Potassium Chloride | 41 | 26 |
| Pregabalin | Pregabalin | 41 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 23 |
| Prednisone | Prednisone | 40 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 19 |
| Meloxicam | Meloxicam | 39 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 32 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | 16 |
| Diazepam | Diazepam | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 28 |
| Clonazepam | Clonazepam | 31 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 15 |
| Metformin Hcl Er | Metformin Hcl | 31 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 19 |
| Mirtazapine | Mirtazapine | 29 | 17 |
| Temazepam | Temazepam | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | 15 |
| Carvedilol | Carvedilol | 28 | 14 |
| Ibuprofen | Ibuprofen | 27 | 12 |
| Ondansetron Odt | Ondansetron | 27 | 16 |
| Donepezil Hcl | Donepezil Hcl | 25 | 16 |
| Fluconazole | Fluconazole | 25 | 20 |
| Jardiance | Empagliflozin | 25 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 24 | 12 |
| Allopurinol | Allopurinol | 23 | 13 |
| Eliquis | Apixaban | 23 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 16 |
| Bupropion Xl | Bupropion Hcl | 22 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | 11 |
| Nystatin | Nystatin | 22 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 16 |
| Cephalexin | Cephalexin | 21 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 20 | 12 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | 14 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Primidone | Primidone | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,416.10 · 132 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, APLENZIN, Auvelity, BREZTRI, Barostim Neo System, CAPLYTA, CHARTIS CATHETER, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, IBSRELA, INSPIRE, INTERSTIM, JARDIANCE, LEQVIO, LINZESS, LO LOESTRIN FE, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, Quviviq, RELISTOR, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, Tymlos, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, VYEPTI, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error